Stages II-IV Ovarian Cancer


Goodbye Brain Fog! Strategies to Help Get Your Thinking Back on Track (March 22, 2017)

Have a Question about Cancer-Related Brain Fog? Ask the Expert! Live Web Chat Tuesday, March 28th, 4:00-5:00 PM, EST Tune in here. Join us for a live Ask the Expert session with neurocognitive expert Heather... Continue Reading

Rubraca™ Is Granted Accelerated Approval for Advanced Ovarian Cancer (December 20, 2016)

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Rubraca™ (rucaparib) for the treatment of women with advanced ovarian cancer who have been treated with two or more chemotherapies... Continue Reading

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer (November 9, 2016)

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed,... Continue Reading

Update on PARP Inhibitors for Ovarian Cancer with BRCA Mutations (October 31, 2016)

Each year in the United States, roughly 22,000 women are diagnosed with ovarian cancer and more than 15,000 die of the disease. Treatment for ovarian cancer commonly involves surgery and/or chemotherapy.... Continue Reading

Tesaro Provides Real Benefit to Ovarian Cancer Patients (October 20, 2016)

Patients with platinum-sensitive recurrent ovarian cancer showed significantly improved cancer-free survival with Tesaro (niraparib) in the first clinical trial directly comparing a poly(ADP)-ribose polymerase... Continue Reading

National Ovarian Cancer Coalition Launches CancerConnect Social Media Platform for Women with Ovarian Cancer (September 26, 2016)

Austin TX/Sun Valley ID–The National Ovarian Cancer Coalition (NOCC) now offers a specialized social network for women with ovarian cancer. The NOCC CancerConnect Community offers these women a safe,... Continue Reading

Pass it On: It’s National Ovarian Cancer Awareness Month (September 15, 2016)

In 2016, the American Cancer Association estimates that 22,280 women will be diagnosed with ovarian cancer, and 14,240 women will die from the disease. The incidence of ovarian cancer has decreased slightly... Continue Reading

FDA Accepts Priority Review of Rucaparib For The Treatment Of Advanced Mutant BRCA Ovarian Cancer (September 6, 2016)

The U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application for the treatment of advanced... Continue Reading

SGO, ASCO Issue New Guidelines for Ovarian Cancer Treatment (August 22, 2016)

A new joint clinical practice guideline from the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology (SGO) states that neoadjuvant chemotherapy (NACT) is the optimal first-line... Continue Reading

Intraperitoneal Chemotherapy Underused in Ovarian Cancer (September 28, 2015)

The use of intraperitoneal (IP) chemotherapy appears to be utilized in fewer than 50% of clinical practices, despite results indicating improved survival with its use in certain patients with ovarian cancer.... Continue Reading

Ovarian Cancer Awareness: Risk, Prevention, Treatment, Survivorship, & Community (September 2, 2015)

As the month of September brings ovarian cancer into focus, it’s time to increase public understanding of the disease, including its prevalence, approaches to screening and prevention, treatment options,... Continue Reading

Personalized Immunotherapy Delays Recurrence in Ovarian Cancer (May 11, 2015)

A new immunotherapy known as Vigil™ may help delay the recurrence of advanced ovarian cancer. These findings were presented at the 2015 Annual Meeting on Women’s Cancer, March 28–31, in Chicago,... Continue Reading

Combination of Avastin®, Taxol®, and Carboplatin Improves Survival in Recurrent Platinum-Sensitive Ovarian Cancer (April 29, 2015)

The addition of Avastin® (bevacizumab) to Taxol® (paclitaxel) and carboplatin for the treatment of recurrent platinum-sensitive ovarian cancer appears to improve survival. These findings were presented... Continue Reading

Lynparza Approved in Advanced Ovarian Cancer (December 29, 2014)

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective... Continue Reading

Adding Cediranib to Olaparib Markedly Improves Progression-Free Survival but Increases Toxicity in Recurrent Platinum-Sensitive Ovarian Cancer (October 21, 2014)

The addition of the antiangiogenic agent cediranib to the PARP inhibitor olaparib in women with recurrent platinum-sensitive ovarian cancer improves time to cancer progression and survival. The results... Continue Reading

Ovarian Cancer Talk: Participate in a Live Video Chat With the Experts from Roswell Park Cancer Institute (September 22, 2014)

Straight from Roswell Park Cancer Institute in Buffalo, N.Y., to your computer or mobile device, four leading experts in ovarian cancer will broadcast a live, interactive video chat from 6 to 7 p.m. on... Continue Reading

National Gynecologic Cancer Awareness Month on CancerConnect (September 9, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of cervical, ovarian and uterine cancer educational programs for national gynecologic cancer awareness month.... Continue Reading

National Ovarian Cancer Awareness Month on CancerConnect (September 2, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of ovarian cancer educational programs for national ovarian cancer awareness month. As the month of September brings... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS